Triamcinolone acetonide sustained-release - Flexion Therapeutics

Drug Profile

Triamcinolone acetonide sustained-release - Flexion Therapeutics

Alternative Names: FX-006; Zilretta

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Flexion Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glucocorticoid receptor agonists; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Musculoskeletal pain

Most Recent Events

  • 04 Apr 2017 Flexion Therapeutics is granted two patents for triamcinolone acetonide sustained-release in USA
  • 21 Feb 2017 Flexion Therapeutics initiates a phase III trial for Musculoskeletal pain (associated with knee osteoarthritis) in USA (Intra-articular) (NCT03046446)
  • 07 Feb 2017 FDA assigns PDUFA action date of 06/10/2017 for triamcinolone acetonide sustained-release for Musculoskeletal pain (associated with knee osteoarthritis)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top